Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
7th grade Avg
|
|
New words:
acetate, activationin, adding, affiliated, affixed, Ahmed, anaphylaxisin, Assignment, asthma, Avval, behalf, Bepler, Biopharma, biotech, Bradley, Bruno, Cantor, cardiac, Cayman, Chem, COG, concurrent, Confidential, connection, Coumadin, courtesy, creative, cultured, Demetri, duly, economic, endeavor, erdtmann, evolve, exclusive, excretion, exempt, expansion, expedite, fast, forward, French, Gautam, gemcitibine, Hamdy, Hashemy, Hodgkin, Holmgren, hydroxyurea, IIa, investor, Jiangsu, Karolinska, Kristin, Kusmartseva, Les, letter, located, main, membrane, mentioned, met, monoclonal, multiply, nonspecific, Pacific, passage, path, PBG, PDF, People, pharma, pontine, prominent, promulgated, Province, purpose, rainer, replied, represented, Republic, requested, retrospectively, rheumatology, ribonuceotide, ribonucleotide, Secretary, Servier, Sharma, Simon, simultaneously, skin, speed, strive, subcutaneously, sublicensing, supply, surrogate, Taizhou, territorial, thereof, thereunder, thereunto, timeline, tongue, undersigned, Ungerstedt, viable, view, website, Wisconsin, withholding, worsened
Removed:
accurate, approve, area, attract, competition, component, expand, fashion, favor, Food, fully, harmed, hazard, hire, implement, incur, intense, lose, manage, manager, managerial, mid, motivate, NDA, neurologic, NSCLC, occur, partnering, pivotal, predict, prevented, previously, prompt, proposed, pursue, SMART, submit, suitable, trend, WBRT
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 4.1 Form of Stock Purchase Agreement
- 10.1 Amendment No. 2 to Assignment Agreement by and Between Pharmacyclics, Inc. and Celera Corporation
- 10.2 Amendment No. 3 to Assignment Agreement by and Between Pharmacyclics, Inc. and Celera Corporation
- 10.3 Amendment No. 1 to Loan Agreement Entered into Between the Company and Robert W. Duggan &Amp; Associates
- 10.4 Offer Letter Dated February 2, 2009 by and Between the Company and Glenn C. Rice, PH.D.
- 10.5 Offer Letter Dated February 5, 2009 by and Between the Company and Rainer Erdtmann.
- 10.6 Offer Letter Dated February 26, 2009 by and Between the Company and Ahmed Hamdy, M.B.B.CH.
- 31.1 CEO 302 Certificate
- 31.2 CFO 302 Certificate
- 32.1 906 Certificate
- PDF 10-Q
- 4.1 Form of Stock Purchase Agreement
- 10.1 Amendment No. 2 to Assignment Agreement by and Between Pharmacyclics, Inc. and Celera Corporation
- 10.2 Amendment No. 3 to Assignment Agreement by and Between Pharmacyclics, Inc. and Celera Corporation
- 10.3 Amendment No. 1 to Loan Agreement Entered into Between the Company and Robert W. Duggan &Amp; Associates
- 10.4 Offer Letter Dated February 2, 2009 by and Between the Company and Glenn C. Rice, PH.D.
- 10.5 Offer Letter Dated February 5, 2009 by and Between the Company and Rainer Erdtmann.
- 10.6 Offer Letter Dated February 26, 2009 by and Between the Company and Ahmed Hamdy, M.B.B.CH.
- 31.1 CEO 302 Certificate
- 31.2 CFO 302 Certificate
- 32.1 906 Certificate
Related press release
PCYC similar filings
External links